Clinical trials are currently being done to study Metformin in combinatory treatments with an assortment of molecularly targeted therapies, including EGFR inhibitors, as well as its effect on overall survival and treatment-related toxicity in advanced stage non-small cell lung cancer patients. Here, EGFR is linked to non-small cell lung carcinoma.